Indan-5-sulfonsaeure | 40117-41-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: Indan-5-sulfonsaeure
• 英文别名: Indan-4-sulfonsaeure；indan-5-sulfonic acid；2,3-dihydro-1H-indene-5-sulfonic acid
• CAS: 40117-41-7
• 化学式: C₉H₁₀O₃S
• 分子量: 198.243
• InChiKey: AILKKOPVJSGLJK-UHFFFAOYSA-N

物化性质

• 熔点：
  86-91 °C
• 密度：
  1.402±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Indan-5-sulfonsaeure 在 lithium aluminium tetrahydride 作用下， 生成 Bis(3,4-trimethylenphenyl)disulfid
  参考文献：
  名称：

  Bock, H.; Hierholzer, B.; Rittmeyer, P., Zeitschrift fur Naturforschung, B: Chemical Sciences, 1989, vol. 44, # 2, p. 187 - 204

  摘要：

  DOI：
• 作为产物：
  描述：

  茚满 在 硫酸 作用下， 生成 Indan-5-sulfonsaeure
  参考文献：
  名称：

  Borsche; Pommer, Chemische Berichte, 1921, vol. 54, p. 109

  摘要：

  DOI：

文献信息

• [EN] HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSES HETEROCYCLIQUES CONVENANT POUR TRAITER DES TROUBLES SENSIBLES A UNE MODULATION DU RECEPTEUR D3 DE LA DOPAMINE
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2006040182A1

  公开（公告）日：2006-04-20

  The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkyl substituted by C3-C6-cycloalkyl, Cl-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6­ alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1 -C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- ­membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4­alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  该发明涉及以下式(I)的化合物，其中n为0、1或2；G为CH2或CHR3；R1为H、C1-C6烷基、被C3-C6环烷基取代的C1-C6烷基、Cl-C6羟基烷基、氟化的C1-C6烷基、C3-C6环烷基、氟化的C3-C6环烷基、C3-C6烯基、氟化的C3-C6烯基、甲酰基、乙酰基或丙酰基；R2、R3和R4独立地为H、甲基、氟甲基、二氟甲基或三氟甲基；A为苯基、吡啶基、嘧啶基、吡嗪基、吡啶嗪基或噻吩基，可以被卤素、甲基、甲氧基和CF3等一个或多个取代基取代；E为NR5或CH2，其中R5为H或C1-C3烷基；Ar为从苯基、含有1、2或3个异原子N、O和S的5-或6-元杂环芳基、以及与饱和或不饱和的5-或6-元碳环或杂环融合的苯基环组成的环状基，其中杂环环包含1、2或3个异原子N、O和S和/或1、2或3个异原子含氮基团，每个基团独立地选择自NR8，其中R8为H、C1-C4烷基、氟化的C1-C4烷基、C1-C4烷基酰基或氟化的C1-C4烷基酰基，环状基Ar可以携带1、2或3个取代基Ra，其中变量Ra具有权利要求和描述中给出的含义；以及其生理上可耐受的酸盐。该发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗易受多巴胺D3受体配体治疗的医疗紊乱的药物组合物。
• Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor
  申请人：Drescher Karla

  公开号：US20080045493A1

  公开（公告）日：2008-02-21

  The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及式(I)的化合物，其中n为0、1或2；G为CH2或CHR3；R1为H、C1-C6烷基、C1-C6烷基取代的C3-C6环烷基、C1-C6羟基烷基、氟代C1-C6烷基、C3-C6环烷基、氟代C3-C6环烷基、C3-C6烯基、氟代C3-C6烯基、甲酰基、乙酰基或丙酰基；R2、R3和R4独立地为H、甲基、氟甲基、二氟甲基或三氟甲基；A为苯基、吡啶基、嘧啶基、吡嗪基、吡啶嗪基或噻吩基，可以被一个或多个卤素、甲基、甲氧基和CF3等取代基所取代；E为NR5或CH2，其中R5为H或C1-C3烷基；Ar为从苯基、一个5-或6-成员的杂环芳基基团中选择的循环基团，该杂环芳基基团的环成员包括1、2或3个从N、O和S选择的杂原子和与饱和或不饱和的5-或6-成员碳环或杂环芳基团融合的苯基环，其中所述杂环芳基团包括1、2或3个从N、O和S选择的杂原子和/或1、2或3个从NR8选择的含杂原子基团，其中R8为H、C1-C4烷基、氟代C1-C4烷基、C1-C4烷基羰基或氟代C1-C4烷基羰基，且所述循环基团Ar可以携带1、2或3个取代基Ra，其中变量Ra的含义如权利要求和说明书中所给出；以及其生理耐受的酸加合盐。本发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗易于用多巴胺D3受体配体治疗的医疗疾病的药物组合物的用途。
• HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR
  申请人：Drescher Karla

  公开号：US20110160176A1

  公开（公告）日：2011-06-30

  The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C,-C 6 -alkyl, C,-C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C,-C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及公式（I）化合物，其中n为0，1或2；G为CH2或CHR3；R1为H，C,-C6-烷基，C,-C6-烷基被C3-C6-环烷基，C1-C6-羟基烷基，氟代C,-C6-烷基，C3-C6-环烷基，氟代C3-C6-环烷基，C3-C6-烯基，氟代C3-C6-烯基，甲酰基，乙酰基或丙酰基取代；R2，R3和R4分别为H，甲基，氟甲基，二氟甲基或三氟甲基；A为苯基，吡啶基，嘧啶基，吡嗪基，吡嗪啉基或噻吩基，可以被一个或多个卤素，甲基，甲氧基和CF3等取代基所取代；E为NR5或CH2，其中R5为H或C1-C3-烷基；Ar为从苯基，一个5-或6-成员的杂环芳基基团，包括由1、2或3个从N、O和S中选择的杂原子作为环成员和与饱和或不饱和的5-或6-成员的碳环或杂环的苯环融合的杂环，其中杂环包含作为环成员的1、2或3个从N、O和S中选择的杂原子和/或1、2或3个杂原子含有的基团，每个基团独立地从NR8中选择，其中R8为H，C1-C4-烷基，氟代C1-C4-烷基，C1-C4-烷基羰基或氟代C1-C4-烷基羰基，其中环状基团Ar可以携带1、2或3个取代基Ra，其中变量Ra在权利要求和说明中给出其含义；以及其生理耐受的酸加盐。本发明还涉及使用公式I化合物或其药学上可接受的盐制备用于治疗可用多巴胺D3受体配体治疗的医学疾病的药物组合物。
• Herbicidal sulfonamides
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0082681A2

  公开（公告）日：1983-06-29

  Sulfonylurea derivatives of the formula wherein Ar is an optionally substituted bicyclic moiety; R, is a substituted mono- or bicyclic heterocyclic moiety; and R10 is H or CH3; and their agriculturally suitable salts exhibit general and selective herbicidal activity. They may be formulated for use in conventional manner. The novel compounds may be made e.g. by reacting an appropriate sulfonyl isocyanate of formula ArSO2NCO with a corresponding heterocyclic amine of formula HNR10R1.

  式中 Ar 为任选取代的双环分子；R 为取代的单环或双环杂环分子；R10 为 H 或 CH3 的磺酰脲衍生物及其农业上适用的盐类具有一般的和选择性的除草活性。 它们可按常规方法配制使用。 新型化合物可通过将式 ArSO2NCO 的适当磺酰基异氰酸酯与相应的式 HNR10R1 的杂环胺反应制成。
• Copolymerisat, Verfahren zu seiner Herstellung und seine Verwendung als Sorptionsmittel
  申请人：CASSELLA Aktiengesellschaft

  公开号：EP0131179A1

  公开（公告）日：1985-01-16

  Das vernetzte Copolymerisat mit 75 bis 99,9 Gew.% wiederkehrender Einheiten einer eine polymerisierbare olefinische Gruppe enthaltenden Pyridyl-, Chinolyl-, Isochinolyl- oder Pyrazinyl-Verbindung, 0,1 bis 25 Gew.% Einheiten eines Vernetzers und 0 bis 25 Gew.% Einheiten einer polymerisierbaren silizium- und/oder bor-organischen Verbindung und, bezogen auf 100 Gew% der Summe der vorgenannten Einheiten, 5 bis 350 Gew.% Einheiten eines N-Vinyl-amids wird durch Perlpolymerisation hergestellt und als Sorptionsmittel für saure Substanzen aus ihren wäßrigen Lösungen verwendet.

  交联共聚物包括 75-99.9%（按重量计）含有可聚合烯烃基的吡啶基、喹啉基、异喹啉基 或吡嗪基化合物的重复单元，0.1-25%（按重量计）的交联剂单元，0-25%（按重量计）的 可聚合有机硅和/或有机硼化合物单元，以及 5-350%（按重量计）的 N-乙烯基酰胺单元。通过珠状聚合法，制备出 % 的可聚合有机硅和/或有机硼化合物单元和 5 至 350 % 的 N-乙烯基酰胺单元（按上述单元重量总和的 100%计算），用作酸性物质水溶液的吸附剂。